West Family Investments Inc. Purchases New Shares in Bristol Myers Squibb Company $BMY

West Family Investments Inc. purchased a new position in shares of Bristol Myers Squibb Company (NYSE:BMY) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 10,464 shares of the biopharmaceutical company’s stock, valued at approximately $603,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Swiss RE Ltd. acquired a new stake in shares of Bristol Myers Squibb during the fourth quarter valued at about $25,000. Darwin Wealth Management LLC purchased a new position in shares of Bristol Myers Squibb during the 2nd quarter valued at approximately $25,000. Physician Wealth Advisors Inc. increased its stake in shares of Bristol Myers Squibb by 73.5% in the fourth quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 202 shares during the last quarter. Bayban acquired a new position in Bristol Myers Squibb during the 4th quarter worth $31,000. Finally, EQ Wealth Advisors LLC bought a new stake in shares of Bristol Myers Squibb in the 4th quarter worth about $32,000. 76.41% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research firms have commented on BMY. Guggenheim reaffirmed a “buy” rating and set a $75.00 target price (up from $72.00) on shares of Bristol Myers Squibb in a report on Friday, July 31st. Wells Fargo & Company set a $65.00 price target on Bristol Myers Squibb and gave the company an “equal weight” rating in a research report on Friday, July 31st. JPMorgan Chase & Co. raised their target price on shares of Bristol Myers Squibb from $67.00 to $73.00 and gave the stock an “overweight” rating in a report on Friday, July 31st. Weiss Ratings upgraded Bristol Myers Squibb from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Tuesday. Finally, Royal Bank Of Canada upped their target price on Bristol Myers Squibb from $60.00 to $64.00 and gave the company a “sector perform” rating in a report on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $66.06.

Bristol Myers Squibb Stock Performance

Shares of BMY stock opened at $67.59 on Thursday. Bristol Myers Squibb Company has a 12-month low of $42.52 and a 12-month high of $68.64. The firm has a market capitalization of $138.06 billion, a price-to-earnings ratio of 14.89, a price-to-earnings-growth ratio of 0.17 and a beta of 0.22. The business has a 50 day simple moving average of $60.18 and a 200 day simple moving average of $59.24. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.53 and a quick ratio of 1.38.

Bristol Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share for the quarter, beating the consensus estimate of $1.60 by $0.44. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.The firm had revenue of $12.97 billion for the quarter, compared to the consensus estimate of $11.74 billion. During the same quarter in the previous year, the business earned $1.46 EPS. The firm’s revenue for the quarter was up 5.7% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. On average, equities research analysts anticipate that Bristol Myers Squibb Company will post 6.95 EPS for the current year.

Bristol Myers Squibb Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, August 3rd. Shareholders of record on Thursday, July 2nd were paid a dividend of $0.63 per share. The ex-dividend date of this dividend was Thursday, July 2nd. This represents a $2.52 annualized dividend and a yield of 3.7%. Bristol Myers Squibb’s dividend payout ratio (DPR) is presently 55.51%.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late?stage pipeline reflect a strong emphasis on cancer and immune?mediated conditions.